These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197 [TBL] [Abstract][Full Text] [Related]
23. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080 [TBL] [Abstract][Full Text] [Related]
24. The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome. Owen RT Drugs Today (Barc); 2012 Nov; 48(11):697-703. PubMed ID: 23170305 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea. Lee EH; Yum MS; Ko TS Clin Neurol Neurosurg; 2013 Jul; 115(7):926-9. PubMed ID: 23083943 [TBL] [Abstract][Full Text] [Related]
26. Clobazam and Aggression-Related Adverse Events in Pediatric Patients With Lennox-Gastaut Syndrome. Paolicchi JM; Ross G; Lee D; Drummond R; Isojarvi J Pediatr Neurol; 2015 Oct; 53(4):338-42. PubMed ID: 26245776 [TBL] [Abstract][Full Text] [Related]
27. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511 [TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833 [TBL] [Abstract][Full Text] [Related]
29. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
30. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695 [TBL] [Abstract][Full Text] [Related]
31. Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome. Kim SH; Eun SH; Kang HC; Kwon EJ; Byeon JH; Lee YM; Lee JS; Eun BL; Kim HD Seizure; 2012 May; 21(4):288-91. PubMed ID: 22421185 [TBL] [Abstract][Full Text] [Related]
32. Clobazam as add-on therapy in children with epileptic encephalopathy. Silva RC; Montenegro MA; Guerreiro CA; Guerreiro MM Can J Neurol Sci; 2006 May; 33(2):209-13. PubMed ID: 16736732 [TBL] [Abstract][Full Text] [Related]
33. An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome. Besag FMC; Vasey MJ Expert Opin Pharmacother; 2019 Sep; 20(13):1563-1574. PubMed ID: 31373526 [No Abstract] [Full Text] [Related]
35. Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome. Purcarin G; Ng YT Ther Adv Neurol Disord; 2014 May; 7(3):169-76. PubMed ID: 24790647 [TBL] [Abstract][Full Text] [Related]
36. Clobazam approved for seizure disorder. Traynor K Am J Health Syst Pharm; 2011 Dec; 68(23):2204. PubMed ID: 22095800 [No Abstract] [Full Text] [Related]
37. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM; N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152 [TBL] [Abstract][Full Text] [Related]
38. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K Epilepsy Res; 2016 Mar; 121():1-7. PubMed ID: 26827266 [TBL] [Abstract][Full Text] [Related]
39. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency. Bergmann KR; Broekhuizen K; Groeneveld GJ Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863 [TBL] [Abstract][Full Text] [Related]
40. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Capovilla G; Verrotti A; Mangano S; Balestri A; Curatolo P; Pascotto A Seizure; 2010 Nov; 19(9):587-91. PubMed ID: 20888268 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]